• Alias: AZD2281, KU-0059436
    • A small-molecule inhibitor of the nuclear enzyme PARP with potential chemosensitizing and radiosensitizing properties
    • FDA approved for advanced ovarian cancer and breast cancer with HER2 negative and BRCA mutation
    • Recommended dose: 400 mg every 12 hours. No grapefruit or Seville oranges
    • Half-life: 11.9 ±4.8 hours
    • Common side effects: Nausea/vomiting, leukopenia/lymphopenia, increased creatinine, fatigue, abdominal pain, diarrhea, anemia, thrombocytopenia, muscle pain, infection
    Other topics in Targeted and Immunotherapy Agents